MBRX Annamycin Fast Track and Orphan Drug Designation from FDA

Moleculin Biotech`s Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases.

the FDA agreed with Moleculin Biotech`s Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to go forward.

This should be an interesting year for MBRX, which is at all time low now.

52 Week Range 1.64 - 8.78

My price target is $3.8